The Pathogenicity of MERS-CoV, SARS-CoV and SARS-CoV-2: A Comparative Overview

被引：0

作者：

Shashank, Patil M. ^{[1
]}

Prithvi, Shirahatti S. ^{[2
]}

Ramith, Ramu ^{[1
]}

机构：

[1] JSS Acad Higher Educ & Res, Sch Life Sci, Dept Biotechnol & Bioinformat, Mysuru 570015, Karnataka, India

[2] Teresian Coll, Dept Biotechnol, Mysuru 570011, Karnataka, India

来源：

RESEARCH JOURNAL OF BIOTECHNOLOGY | 2021年 / 16卷 / 01期

关键词：

SARS-CoV; MERS-CoV; Pathogenesis; Transmission; Infection; COVID-19; INFECTION; CORONAVIRUS; INHIBITORS; EVOLUTION; ORIGIN;

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The ongoing detrimental consequences of SARS-CoV-2 or COVID-19 are attributable to its remarkable pathogenesis and modes of transmission. Originating from a common ancestor of the previous coronavirus outbreaks, MERS-CoV and SARS-CoV-1, the former has been evolved in terms of its pathogenic mechanisms, routes of transmission and the extent of infection. The comprehensive evaluation of these modifications at the molecular level would reveal astonishing details about the extensive lethality of the current SARS-CoV-2 outbreak. Further, these details can be utilized for the development of effective and specific treatment methods. This review elaborates the comparative assessment of the viral characteristics of coronaviruses: MERS-CoV, SARS-CoV-1 and SARSCoV-2. With the comparative account, the study endeavours to leave a clear picture explaining the reason behind the extensive lethality of the current SARS-CoV-2 pandemic.

引用

页码：182 / 192

页数：11

共 82 条

[1] Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease [J].

Agostini, Maria L. ;

Andres, Erica L. ;

Sims, Amy C. ;

Graham, Rachel L. ;

Sheahan, Timothy P. ;

Lu, Xiaotao ;

Smith, Everett Clinton ;

Case, James Brett ;

Feng, Joy Y. ;

Jordan, Robert ;

Ray, Adrian S. ;

Cihlar, Tomas ;

Siegel, Dustin ;

Mackman, Richard L. ;

Clarke, Michael O. ;

Baric, Ralph S. ;

Denison, Mark R. .

MBIO, 2018, 9 (02)

[2]

[Anonymous], 2008, P NATL ACAD SCI US, DOI DOI 10.1109/ICRMEM.2008.25

[3] CRISPR-Cas14 is now part of the artillery for gene editing and molecular diagnostic [J].

Aquino-Jarquin, Guillermo .

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2019, 18 :428-431

[4] Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) [J].

Arabi, Y. M. ;

Harthi, A. ;

Hussein, J. ;

Bouchama, A. ;

Johani, S. ;

Hajeer, A. H. ;

Saeed, B. T. ;

Wahbi, A. ;

Saedy, A. ;

AlDabbagh, T. ;

Okaili, R. ;

Sadat, M. ;

Balkhy, H. .

INFECTION, 2015, 43 (04) :495-501

[5] Molecular Pathogenesis of Middle East Respiratory Syndrome (MERS) Coronavirus [J].

Banerjee, Arinjay ;

Bald, Kaushal ;

Mossman, Karen .

CURRENT CLINICAL MICROBIOLOGY REPORTS, 2019, 6 (03) :139-147

[6] Viral glycoproteins: biological role and application in diagnosis [J].

Banerjee N. ;

Mukhopadhyay S. .

VirusDisease, 2016, 27 (1) :1-11

[7] Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019 [J].

Barlow, Ashley ;

Landolf, Kaitlin M. ;

Barlow, Brooke ;

Yeung, Siu Yan Amy ;

Heavner, Jason J. ;

Claassen, Cassidy W. ;

Heavner, Mojdeh S. .

PHARMACOTHERAPY, 2020, 40 (05) :416-437

[8]

Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]

[9] SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review [J].

Carvalho Nascimento Junior, Jose Adao ;

Santos, Anamaria Mendonca ;

Quintans-Junior, Lucindo Jose ;

Bandero Walker, Cristiani Isabel ;

Borges, Lysandro Pinto ;

Serafini, Mairim Russo .

EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (08) :567-579

[10]

Centre for disease control and prevention, 2020, MIDDL E RESP SYNDR M

← 1 2 3 4 5 6 7 8 9 →